Geode Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-389,041
| Closed | -$1.44M | – | 4113 |
|
|
2017
Q4 | $1.44M | Buy |
389,041
+42,439
| +12% | +$174K | ﹤0.01% | 2944 |
|
|
2017
Q3 | $1.42M | Buy |
346,602
+40,423
| +13% | +$155K | ﹤0.01% | 2951 |
|
|
2017
Q2 | $1.14M | Buy |
306,179
+53,245
| +21% | +$211K | ﹤0.01% | 3050 |
|
|
2017
Q1 | $1.05M | Buy |
252,934
+137,350
| +119% | +$577K | ﹤0.01% | 2993 |
|
|
2016
Q4 | $498K | Buy |
115,584
+2,351
| +2% | +$15.2K | ﹤0.01% | 3265 |
|
|
2016
Q3 | $1.11M | Buy |
113,233
+24,481
| +28% | +$174K | ﹤0.01% | 2883 |
|
|
2016
Q2 | $502K | Sell |
88,752
-16,220
| -15% | -$110K | ﹤0.01% | 3223 |
|
|
2016
Q1 | $799 | Buy |
104,972
+1,135
| +1% | +$8.74K | ﹤0.01% | 3002 |
|
|
2015
Q4 | $1.38M | Buy |
103,837
+2,397
| +2% | +$41.3K | ﹤0.01% | 2720 |
|
|
2015
Q3 | $1.67M | Buy |
101,440
+968
| +1% | +$19.8K | ﹤0.01% | 2561 |
|
|
2015
Q2 | $2.25M | Buy |
100,472
+4,459
| +5% | +$70.5K | ﹤0.01% | 2420 |
|
|
2015
Q1 | $939K | Buy |
96,013
+19,335
| +25% | +$190K | ﹤0.01% | 2911 |
|
|
2014
Q4 | $874K | Buy |
76,678
+8,559
| +13% | +$92.9K | ﹤0.01% | 2927 |
|
|
2014
Q3 | $784K | Buy |
68,119
+12,476
| +22% | +$191K | ﹤0.01% | 2938 |
|
|
2014
Q2 | $1.08M | Buy |
55,643
+13,779
| +33% | +$243K | ﹤0.01% | 2758 |
|
|
2014
Q1 | $751K | Buy |
41,864
+6,663
| +19% | +$109K | ﹤0.01% | 2946 |
|
|
2013
Q4 | $371K | Buy |
35,201
+54
| +0.2% | +$604 | ﹤0.01% | 3205 |
|
|
2013
Q3 | $434K | Buy |
35,147
+11
| +0% | +$116 | ﹤0.01% | 3017 |
|
|
2013
Q2 | $329K | Buy |
+35,136
| New | +$451K | ﹤0.01% | 3056 |
|
Geode Capital Management's CASC Position: Q1 2018 in Review
Geode Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 389,041 shares — an estimated $1.44M sold.
Geode Capital Management first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $2.25M in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Geode Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Geode Capital Management sold 389,041 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $1.44M.
- Geode Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Geode Capital Management's Cascadian Therapeutics, Inc. position peaked at $2.25M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Geode Capital Management's 13F filing for Q1 2018, filed 15 May 2018.